Repro Med Systems Inc (KRMD)

This article provides access to the stock options chain, quotes, and news for KORU Medical Systems (KRMD). It serves as a resource for investors interested in this medical device company's financial information and market performance.

KORU Medical Systems (NASDAQ:KRMD) surpassed revenue expectations in its recent quarterly report, though its stock saw a 14% drop. Analysts maintained their revenue forecasts for 2026 at US$48.1m, an expected 6.6% increase, but modestly raised loss-per-share forecasts to US$0.047. Despite these adjustments, the consensus price target of US$6.60 remains unchanged, indicating analysts believe the company is performing as expected with long-term growth prospects outperforming the industry.

KORU Medical Systems (KRMD) saw its stock price drop 13.8% despite reporting a small profit and record Q2 revenue of US$12.0m. The market reacted negatively to the company's trimmed full-year revenue guidance and concerns about the timing of growth and execution risks. While the company achieved positive net income and improved gross margins, bears highlight concentration risk, slower international launches, and the delayed oncology consumables opportunity.

CCORF has reiterated its Buy rating for KORU Medical Systems (KRMD.US) and maintained its target price at $6. This indicates a continued positive outlook on the company's stock performance from CCORF.

KORU Medical Systems Inc (KRMD) reported record quarterly revenue of $12 million, an 18% increase year-over-year, and achieved positive net income for the first time since 2019. Despite this, the company narrowed its full-year revenue guidance due to slower-than-expected growth in international pre-filled syringe markets and the withdrawal of its U.S. FDA application for FESGO, impacting its oncology market entry. KORU is pivoting to alternative oncology molecules and focusing on long-term growth through international expansion and new drug indications.